Tiger BioSciences Expands with HealPACK Acquisition
Tiger BioSciences has made a significant move in the healthcare sector by acquiring Encore Surgical HealPACK Solutions through its wholly owned subsidiary, Tiger Wound Care. This acquisition marks a thrilling advancement in the way postoperative care is delivered. By integrating Encore’s innovative HealPACK, Tiger BioSciences aims to enhance patient recovery experiences, emphasizing at-home treatment that matches the burgeoning demands of modern wound care.
The HealPACK Innovation
The HealPACK offers an advanced surgical dressing solution that is conveniently delivered to the patient’s home, ensuring that they can manage their recovery in a familiar environment. Designed with the patients' needs in mind, the HealPACK includes a premium selection of surgical dressing products that have gained the trust of physicians across the nation. This initiative not only reduces hospital visits but promotes a proactive approach to wound care right from the patient's doorstep.
Technological Integration with HealAPP
Alongside the product, the HealPACK comes equipped with a dedicated HealAPP. This app streamlines the ordering process by assisting with prescription and insurance verification to ensure patients receive the care they need without unnecessary delays. Moreover, it facilitates accurate documentation, which is vital for insurers’ reimbursement processes. Such advancements are geared towards improving compliance and enhancing the overall efficiency of wound care management.
Leadership Insights
Miro Kesic, CEO of Encore, elaborated on the company's rapid ascension to becoming a market leader. He expressed his confidence in the HealPACK's potential to empower physicians significantly, attributing their success to a blend of robust technology and exceptional teamwork. Neall French, President of Encore, echoed this sentiment, highlighting the strategic alignment of HealPACK with Tiger BioSciences as a crucial step toward continuous innovation in the industry.
Benefits of the Acquisition
The addition of HealPACK and HealAPP into the Tiger BioSciences portfolio promises not only to enhance the wound care offerings but also to expand the reach of their product line into orthopedic, podiatry, and plastic surgery markets. Co-CEO Oliver Burckhardt expressed enthusiasm about this collaboration, underscoring the importance of creating synergies between the two companies to better serve patients and providers alike.
About Tiger BioSciences
Tiger BioSciences is a pioneer in the field of regenerative medicine, continuously striving to innovate in cell and tissue technologies. They focus on developing compliant tissue engineering solutions, which are essential for the advancement of medical practices today. The company’s mission revolves around vertically integrating all aspects of modern engineering, ensuring a holistic approach from conception through to distribution.
Contact Information
For more information about Tiger BioSciences and their recent acquisition, you can reach out to Larry R. Wood, Jr., Chief Legal Officer, or Craig Waters, Chief Financial Officer of Novo Healthcare Services, for further details.
Frequently Asked Questions
What is the HealPACK?
The HealPACK is an advanced surgical dressing solution that enhances at-home recovery for patients who have undergone surgery.
How does the HealAPP support patients?
The HealAPP assists with prescription management and insurance verification to ensure timely access to wound care products.
Who leads Encore Surgical?
Miro Kesic serves as the CEO, while Neall French acts as the President of Encore Surgical.
What is Tiger BioSciences known for?
Tiger BioSciences is recognized for its advancements in regenerative medicine and tissue engineering technologies.
What markets does this acquisition impact?
The acquisition enhances Tiger BioSciences' offerings in orthopedic, podiatry, and plastic surgery markets, extending their influence in the healthcare sector.
